Skip to main content

Table 3 Clinical and demographic characteristics in patients with and without HCC occurrence—univariate and multivariate analysis

From: Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Parameters

Univariate analysis

Multivariate analysis (cirrhosis)

Multivariate analysis (Child–Pugh)

Patients without HCC (n = 950)

Patients with HCC (n = 35)

p

O.R. [95% C.I.]

p

O.R. [95% C.I.]

p

Male gender, n (%)

518 (54.5)

25 (71.4)

0.048

2.852 [1.162–6.999]

0.022

2.738 [1.109–6.762]

0.029

Age, years, median [IQR]

67 [59–73]

69 [64–74]

0.045

    

BMI, kg/m2, median [IQR]

26 [24–28.4]

25.4 [23.4–28]

0.17

    

Presence of diabetes, n (%)

121 (12.8)

10 (28.6)

0.007

0.392 [0.155–0.988]

0.047

0.369 [0.146–0.931]

0.047

Presence of cirrhosis, n (%)

696 (73.4)

35 (100)

0.002

0.153 [0.019–1.239]

0.079

  

CTP B classa n (%)

72/696 (10.3)

10/34 (29.4)

0.001

  

0.430 [0.170–1.086]

0.074

HCV genotype 1, n (%)

724 (77.3)

29 (82.9)

0.44

    

24 weeks treatment duration, n (%)

354 (37.3)

19 (54.3)

0.041

    

Baseline HCV-RNA, UI/ml, median [IQR]

995,500 [350,000–2,646,500]

729,000 [290,000–1,238,000]

0.123

    

Liver stiffness, kPa, median [IQR]

14.9 [11.8–22]

32 [18.5–44.4]

< 0.0001

1.048 [1.020–1.077]

0.001

1.057 [1.031–1.084]

0.000

SVR12, n (%)

933 (98.2)

33 (94.3)

0.09

    

DAA-SOF based, n (%)

707 (74.6)

31 (88.6)

0.09

    

DAA-RBV included, n (%)

690 (72.8)

15 (42.9)

< 0.0001

    

DAA-SOF + RBV, n (%)

562 (59.2)

12 (34.3)

0.003

    

DAA-SOF without RBV, n (%)

145 (20.5)

19 (61.3)

0.003

15.363 [6.668–35.396]

0.000

0.059 [0.025–0.137]

0.000

  1. aComputed based on number of cirrhotic patients